Inhaled budesonide therapy for patients with stable COPD

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Corticosteroids offer benefits for some COPD patients, but side effects are a concern.
• Inhaled steroids present a safer long-term treatment option for COPD management.
• Identifying steroid responders is crucial for optimizing COPD treatment.

Purpose of the Study:

• To investigate the efficacy of high-dose inhaled budesonide in improving COPD symptoms and pulmonary function.
• To determine if response to inhaled beta-2 agonists can predict steroid responsiveness in COPD patients.

Main Methods:

• A double-blind, placebo-controlled crossover trial involving 30 stable COPD patients.
• Patients were divided into two groups: 8 responders and 22 non-responders to inhaled beta-2 agonists.
• Treatment involved a 6-week course of 800 micrograms/day inhaled budesonide versus placebo, with a 4-week washout period.

Main Results:

• Significant improvement in FEV1 (forced expiratory volume in 1 second) was observed in 6 of 8 beta-2 agonist responders treated with budesonide compared to placebo.
• No significant improvement in mean FEV1 was noted in the 22 non-responders.
• Responders showed a significant reduction in daily beta-2 agonist use during budesonide treatment (2.4 puffs/day) versus placebo (5.3 puffs/day).
• Non-responders exhibited similar beta-2 agonist consumption regardless of treatment (4.8 puffs/day with budesonide vs. 5.0 puffs/day with placebo).

Conclusions:

• Inhaled steroids, specifically budesonide, improve spirometry and reduce reliever medication needs in approximately 25% of stable COPD patients.
• The likelihood of benefiting from inhaled steroids increases to about 75% in COPD patients who demonstrate a positive response to inhaled beta-2 agonists.
• Beta-2 agonist response serves as a valuable indicator for personalizing inhaled steroid therapy in COPD.